In contrast, severe COVID-19 patients persistently treated with an ACE inhibitor/Angiotensin II receptor blocker had a higher risk of acute renal damage compared to the 149 individuals from the Referral Center Cohort in the northeast of France [129]. Here, ACE is linked to COVID-19.